Company: SION
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0002036042-25-000005
Chunk: 218

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 8
Chunk 218
---
 investing activities(126,913)27,352 Cash flows from financing activities:Proceeds from issuance of Series C convertible preferred stock, net of issuance costs181,328 — Payment of deferred offering costs(2,502)— Exercise of common stock options141 31 Net cash provided by financing activities178,967 31 Net decrease in cash, cash equivalents and restricted cash(733)(16,316)Cash, cash equivalents and restricted cash at beginning of period39,483 55,799 Cash, cash equivalents and restricted cash at end of period$38,750 $39,483 Supplemental disclosure of non-cash investing and financing activities:Deferred offering costs in accrued expenses$492 $— Right-of use asset obtained in exchange for new operating lease liability— 9,516 Reconciliation of cash, cash equivalents and restricted cash:Cash and cash equivalents$37,788 $38,521 Restricted cash962 962 Total cash, cash equivalents, and restricted cash$38,750 $39,483 

The accompanying notes are an integral part of these consolidated financial statements. 

F-6